Akers Biosciences Announces Second Quarter Trading Update
August 03 2017 - 10:39AM
Marketwired
Akers Biosciences Announces Second Quarter Trading Update
Second Quarter Revenues Up 25% over Q2 2016
THOROFARE, NJ Akers Biosciences, Inc. (NASDAQ: AKER) (AIM:
AKR.L), ("Akers Bio" or the "Company"), a developer of rapid health
information technologies, announces that sales in the second
quarter ended June 30, 2017 were among the strongest since the
Company's admission to NASDAQ Capital Market in 2014.
The Company recorded revenues of approximately $1.2 million over
the three-month period, representing an increase of approximately
25 percent over the second quarter of 2016, and a 1.8 times
increase over the first quarter of 2017. Revenues were derived from
product sales in all key geographic regions (U.S., China and Rest
of World) and were comprised of sales across Akers Bio's core
commercialized product lines including components associated with
the Company's PIFA Heparin/PF4 Rapid Assay products for sale
internationally, and MPC breathalyzer based products.
Akers Bio intends to file its Form 10-Q containing the financial
statements for the three months and six months ended June 30, 2017
after U.S. market close on Monday, August 14, 2017.
Notice of Conference Call
Akers Bio will hold a conference call on Tuesday, August 15,
2017 at 09:00 a.m. Eastern Time to discuss its earnings for the
three months and six months ended June 30, 2017. Management will be
available during a question-and-answer session.
To participate in the call from within the U.S., please dial
1-800-210-9006 approximately 10 minutes prior to the scheduled
start time. International callers should dial 1-719-457-2602. The
Conference ID is 7353698. Interested parties can also listen via a
live Internet webcast, which can be found at
http://public.viavid.com/index.php?id=125855.
A recording of the call will be available in the Investor Center
of the Company's website at
http://www.akersbio.com/investor-center.
About Akers Biosciences, Inc.
Akers Bio develops, manufactures, and supplies rapid screening
and testing products designed to deliver quicker and more
cost-effective healthcare information to healthcare providers and
consumers. The Company has advanced the science of diagnostics
while responding to major shifts in healthcare through the
development of several proprietary platform technologies. The
Company's state-of-the-art rapid diagnostic assays can be performed
virtually anywhere in minutes when time is of the essence. The
Company has aligned with major healthcare companies and high volume
medical product distributors to maximize product offerings, and to
be a major worldwide competitor in diagnostics.
Additional information on the Company and its products can be
found at www.akersbio.com. Follow us on
Twitter @AkersBio.
Cautionary Statement Regarding Forward
Looking Statements
Statements contained herein that are not
based upon current or historical fact are forward-looking in nature
and constitute forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934. Such forward-looking statements
reflect the Company's expectations about its future operating
results, performance and opportunities that involve substantial
risks and uncertainties. These statements include but are not
limited to statements regarding the intended terms of the offering,
closing of the offering and use of any proceeds from the offering.
When used herein, the words "anticipate," "believe," "estimate,"
"upcoming," "plan," "target", "intend" and "expect" and similar
expressions, as they relate to Akers Biosciences, Inc., its
subsidiaries, or its management, are intended to identify such
forward-looking statements. These forward-looking statements are
based on information currently available to the Company and are
subject to a number of risks, uncertainties, and other factors that
could cause the Company's actual results, performance, prospects,
and opportunities to differ materially from those expressed in, or
implied by, these forward-looking statements.
For more information:
Akers Biosciences, Inc.
John J. Gormally Chief Executive
Officer
Raymond F. Akers, Jr. PhD Vice Chairman &
Chief Scientific Director
Tel. +1 856 848 8698
Taglich Brothers, Inc. (Investor
Relations)
Chris Schreiber
Tel. +1 917 445 6207
Email: cs@taglichbrothers.com
finnCap (UK Nominated Adviser and Broker)
Adrian Hargrave / Scott Mathieson (Corporate Finance)
Steve Norcross (Broking)
Tel. +44 (0)20 7220 0500
Vigo Communications (Global Public
Relations)
Ben Simons / Fiona Henson
Tel. +44 (0)20 7830 9704
Email: akers@vigocomms.com
Akers Biosciences (LSE:AKR)
Historical Stock Chart
From Apr 2024 to May 2024
Akers Biosciences (LSE:AKR)
Historical Stock Chart
From May 2023 to May 2024